Expert Panel Recommendations: Based on the CAPItello‐291 study [51], capivasertib combined with fulvestrant is recommended for patients with locally advanced or metastatic HR‐positive/HER2‐negative breast cancer who exhibit any gene alterations in PIK3CA, AKT1, or PTEN. Here, ERBB2 is linked to breast cancer.